Shared on01 Aug 25Fair value Increased 31%
The notable increase in Exagen’s consensus price target reflects improvements in profitability as evidenced by a higher net profit margin, alongside a rising future P/E, resulting in a revised fair value of $10.83 per share. What's in the News Exagen expects 2025 full-year revenue between $65 million and $70 million and aims for positive adjusted EBITDA in the fourth quarter if the high end is achieved.
Shared on24 Apr 25Fair value Decreased 14%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.